Nowadays, there are about 50 million people suffering from dementia worldwide. In 2030, it is expected that there will be 82 million people living with dementia and in 2050, their number should reach 152 million. This increase in the number of people with dementia results in significant social and economic problems. Therefore, researchers attempt to reduce risk factors causing the development of dementia such as high blood pressure. Epidemiological studies have shown that hypertension increases the risk of dementia at an older age. It can, therefore, be assumed that hypertension therapy will reduce the risk of dementia. However, previous clinical studies have shown that the efficacy of different antihypertensive drugs differs in this respect. The drug group that appears to be the most effective in these analyses is calcium channel blockers (CCBs). The most significant preventive efficacy in terms of protection against dementia has been demonstrated with nitrendipine. Its use is, therefore, particularly advantageous in elderly patients with systolic hypertension who are at high risk of dementia. The purpose of this study is to restore the discussion on the prevention of vascular dementia and Alzheimer's dementia with nitrendipine in indicated hypertonic patients. The authors performed a literature search of available sources describing the issue of dementia, hypertension and its treatment with nitrendipine. In addition, they made a comparison and evaluation of relevant findings. The results of the detected research studies indicate that nitrendipine is able to reduce the incidence of dementia [Alzheimer's disease (AD), vascular and mixed] by 55%. The treatment of 1,000 patients with nitrendipine for 5 years may prevent 20 cases of dementia. However, what has not yet been explained is the temporal link between hypertension and dementia due to the long-time intervals between hypertension and the development of dementia.

Biomedical Research Centrum University Hospital Hradec Králové Hradec Králové Czechia

Department of Neurology University Hospital Hradec Králové Hradec Králové Czechia

Faculty of Informatics and Management University of Hradec Králové Hradec Králové Czechia

Zobrazit více v PubMed

Agamanolis D. (2012). Dementia. Available online at: http://neuropathology-web.org/chapter9/chapter9aDementia.html [accessed June 2, 2018].

Alzheimer’s Association (2015). Alzheimer’s disease facts and figures. Alzheimers Dement. 11, 332–384. PubMed

Appleby B. S., Nacopoulos D., Milano N. Z. K., Cummings J. L. (2013). A review: treatment of Alzheimer’s disease discovered in repurposed agents. Dement. Geriatr. Cogn. Disord. 35, 1–22. 10.1159/000345791 PubMed DOI

Bachmeier C., Beaulieu-Abdelahad D., Mullan M., Paris D. (2011). Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. Eur. J. Pharmacol. 659, 124–129. 10.1016/j.ejphar.2011.03.048 PubMed DOI

Capone C., Faraco G., Coleman C., Young C. N., Pickel V. M., Anrather J., et al. . (2012). Endothelin 1-dependent neurovascular dysfunction in chronic intermittent hypoxia. Hypertension 60, 106–113. 10.1161/HYPERTENSIONAHA.112.193672 PubMed DOI PMC

Cummings J. L. (2004). Alzheimer’s disease. N Engl. J Med. 351, 56–67. 10.1056/NEJMra040223 PubMed DOI

Cummings J., Lee G., Ritter A., Zhong K. (2018). Alzheimer’s disease drug development pipeline: 2018. Alzheimers. Dement. N Y 4, 195–214. 10.1016/j.jalz.2018.02.007 PubMed DOI PMC

Deanfield J. E., Detry J.-M. R. G., Lichtlen P. R., Magnani B., Sellier P., Thaulow E. (1994). Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease double-blind circadian anti-ischemia program in europe (CAPE Trial). J. Am. Coll. Cardiol. 24, 1460–1467. 10.1016/0735-1097(94)90140-6 PubMed DOI

Dickstein D. L., Walsh J., Brautigam H., Stockton S. D., Gandy S., Hof P. R. (2010). Role of vascular risk factors and vascular dysfunction in Alzheimer’s disease. Mt. Sinai J. Med. 77, 82–102. 10.1002/msj.20155 PubMed DOI PMC

Durgan D. J., Bryan R. M., Jr. (2012). Cerebrovascular consequences of obstructive sleep apnea. J. Am. Heart Assoc. 1:e000091. 10.1161/JAHA.111.000091 PubMed DOI PMC

Elias M. F., Goodell A. L., Dore G. A. (2012). Hypertension and cognitive functioning: a perspective in historical context. Hypertension 60, 260–268. 10.1161/HYPERTENSIONAHA.111.186429 PubMed DOI

Elias M. F., Wolf P. A., D’Agostino R. B., Cobb J., White L. R. (1993). Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am. J. Epidemiol. 138, 353–364. 10.1093/oxfordjournals.aje.a116868 PubMed DOI

Elliott W. J., Ram C. V. (2011). Calcium channel blockers. J. Clin. Hypertens. 13, 687–689. 10.1111/j.1751-7176.2011.00513.x PubMed DOI PMC

Faraco G., Iadecola C. (2013). Hypertension: a harbinger of stroke and dementia. Hypertension 62, 810–817. 10.1161/HYPERTENSIONAHA.113.01063 PubMed DOI PMC

Farmer M. E., Kittner S. J., Abbott R. D., Wolz M. M., Wolf P. A., White L. R. (1990). Longitudinally measured blood pressure, antihypertensive medication use and cognitive performance: the Framingham Study. J. Clin. Epidemiol. 43, 475–480. 10.1016/0895-4356(90)90136-d PubMed DOI

Forette F., Seux M.-L., Staessen J. A., Thijs L., Birkenhäger W. H., Babarskiene M. R., et al. . (1998). Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352, 1347–1351. 10.1016/s0140-6736(98)03086-4 PubMed DOI

Forette F., Seux M. L., Staessen J. A., Thijs L., Babarskiene M. R., Babeanu S., et al. . (2002). The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch. Intern Med. 162, 2046–2052. 10.1001/archinte.162.18.2046 PubMed DOI

Gibson R. S., Boden W. E. (1996). Calcium channel antagonists: friend or foe in postinfarction patients? Am. J. Hypertens. 9, 172S–176S. 10.1016/s0895-7061(96)90097-7 PubMed DOI

Guo Z., Viitanen M., Fratiglioni L., Winblad B. (1996). Low blood pressure and dementia in elderly people: the kungsholmen project. BMJ 312, 805–808. 10.1136/bmj.312.7034.805 PubMed DOI PMC

Hanon O. (2010). Hypertension in the elderly and risk of dementia. J. Neurol. Sci. 60, 649–653. PubMed

Held P. H., Yusuf S. (1994). Calcium antagonists in the treatment of ischemic heart disease: myocardial infarction. Coron. Artery Dis. 5, 21–26. 10.1097/00019501-199401000-00004 PubMed DOI

Hockerman G. H., Johnson B. D., Abbott M. R., Scheuer T., Catterall W. A. (1997). Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels in transmembrane segment IIIS6 and the pore region of the α1 subunit. J. Biol. Chem. 272, 18759–18765. 10.1074/jbc.272.30.18759 PubMed DOI

Klimova B., Kuca K. (2016). Speech and language impairments in dementia. J. Appl. Biomed. 14, 97–103. 10.1044/policy.gl1991-00051 DOI

Klimova B., Maresova P., Kuca K. (2016). Assistive technologies in managing language disorders in dementia. Neuropsychiatr. Dis. Treat. 12, 533–540. 10.2147/NDT.S95903 PubMed DOI PMC

Klimova B., Maresova P., Valis M., Hort J., Kuca K. (2015). Alzheimer’s disease and language impairments: social intervention and medical treatment. Clin. Interv. Aging 10, 1401–1408. 10.2147/CIA.S89714 PubMed DOI PMC

LaFerla F. (2002). Calcium dyshomeostasis and intracellular signaling in Alzheimer’s Disease. Nat. Rev. Neurosci. 3, 862–872. 10.1038/nrn960 PubMed DOI

Launer L. J., Ross G. W., Petrovitch H., Masaki K., Foley D., White L. R., et al. . (2000). Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 21, 49–55. 10.1016/S0197-4580(00)00096-8 PubMed DOI

Lever A. F., Brennan P. J. (1993). MRC trial of treatment in elderly hypertensives. Clin. Exp. Hypertens. 15, 941–952. 10.3109/10641969309037083 PubMed DOI

Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., et al. . (2003). The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. 21, 875–886. 10.1097/01.hjh.0000059028.82022.89 PubMed DOI

Maresova P., Klimova B., Novotny M., Kuca K. (2016). Alzheimer’s and Parkinson’s diseases: expected economic impact on europe—a call for a uniform european strategy. J. Alzheimers Dis. 54, 1123–1133. 10.3233/JAD-160484 PubMed DOI

Maxwell C. J., Hogan D. B., Ebly E. M. (1999). Calcium-channel blockers and cognitive function in elderly people: results from the Canadian study of health and aging. CMAJ 161, 501–506. 10.1136/bmj.319.7213.806b PubMed DOI PMC

Mitchell A. J., Meader N., Pentzek M. (2011). Clinical recognition of dementia and cognitive impairment in primary care: a meta-analysis of physician accuracy. Acta Psychiatr. Scand. 124, 165–183. 10.1111/j.1600-0447.2011.01730.x PubMed DOI

Morris J. C. (1996). Classification of dementia and Alzheimer’s disease. Acta Neurol. Scand. 165, 41–50. PubMed

Morris M. C., Scherr P. A., Hebert L. E., Bennett D. A., Wilson R. S., Glynn R. J., et al. . (2000). The cross-sectional association between blood pressure and Alzheimer’s disease in a biracial community population of older persons. J. Gerontol. A 55, M130–M136. 10.1093/gerona/55.3.M130 PubMed DOI

Neal B., MacMahon S. (1995). The progress study: rationale and design. J. Hypertens. 13, 1869–1873. PubMed

Nieoullon A. (2011). Neurodegenerative diseases and neuroprotection: current views and prospects. J. Appl. Biomed. 9, 173–183. 10.2478/v10136-011-0013-4 DOI

Nimmrich V., Eckert A. (2013). Calcium channel blockers and dementia. Br. J. Pharmacol. 169, 1203–1210. 10.1111/bph.12240 PubMed DOI PMC

Paris D., Bachmeier C., Patel N., Quadros A., Volmar C. H., Laporte V., et al. . (2011). Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Mol. Med. 17, 149–162. 10.2119/molmed.2010.00180 PubMed DOI PMC

Park L., Zhou J., Zhou P., Pistick R., El Jamal S., Younkin L., et al. . (2013). Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. U S A 110, 3089–3094. 10.1073/pnas.1300021110 PubMed DOI PMC

Parsons C., Murad M. H., Andersen S., mookadam F., Labonte H. (2016). The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta-analysis. Future Cardiol. 12, 237–248. 10.2217/fca.15.90 PubMed DOI

Peters R., Beckett N., Forette F., Tuomilehto J., Clarke R., Ritchie C., et al. . (2008). Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 7, 683–689. 10.1016/S1474-4422(08)70143-1 PubMed DOI

Pitt B., Byington R. P., Furberg C. D., Hunninghake D. B., Mancini G. B., Miller M. E., et al. . (2000). Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102, 1503–1510. 10.1161/01.cir.102.13.1503 PubMed DOI

Plum F. (1986). The pathophysiology of dementia. Gerontology 32, 67–72. 10.1159/000212832 PubMed DOI

Prince M., Cullen M., Mann A. (1994). Risk factors for Alzheimer’s disease and dementia: a case control study based on the MRC elderly hypertension trial. Neurology 44, 97–104. PubMed

Ravaglia G., Forti P., Maioli F., Martelli M., Servadei L., Brunetti N., et al. . (2006). Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk factors. Dement. Geriatr. Cogn. Disord. 21, 51–58. 10.1159/000089515 PubMed DOI

Rehnqvist N., Hjemdahl P., Billing E., Björkander I., Eriksson S. V., Forslund L., et al. . (1996). Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur. Heart J. 17, 76–81. PubMed

Rodrigue K. M., Rieck J. R., Kennedy K. M., Devous M. D., Diaz-Arrastia R., Park D. C. (2013). Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol. 70, 600–606. 10.1001/jamaneurol.2013.1342 PubMed DOI PMC

Ruitenberg A., Skoog I., Ott A., Aevarsson O., Witteman J. C., Lernfelt B., et al. . (2001). Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement. Geriatr. Cogn. Disord. 12, 33–39. 10.1159/000051233 PubMed DOI

Sen A. P., Boksa P., Quirion R. (1993). Brain calcium channel related dihydropyridine and phenylalkylamine binding sites in Alzheimer’s Parkinson’s and Huntington’s diseases. Brain Res. 611, 216–221. 10.1016/0006-8993(93)90505-h PubMed DOI

SHEP Cooperative Research Group . (1991). Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265, 3255–3264. PubMed

Sierra C., Doménech M., Camafort M., Coca A. (2012). Hypertension and mild cognitive impairment. Curr. Hypertens. Rep. 14, 548–555. 10.1007/s11906-012-0315-2 PubMed DOI

Skinner M. H., Futterman A., Morrissette D., Thompson L. W., Hoffman B. B., Blaschke T. F. (1992). Atenolol compared with nifedipine: effect on cognitive function and mood in elderly hypertensive patients. Ann. Intern. Med. 116, 615–623. 10.7326/0003-4819-116-8-615 PubMed DOI

Skoog I., Lernfelt B., Landahl S., Palmertz B., Andreasson L. A., Nilsson L., et al. . (1996). 15-year longitudinal study of blood pressure and dementia. Lancet 347, 1141–1145. PubMed

Staessen J. A., Thijs L., Richart T., Odili A. N., Birkenhäger W. H. (2011). Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension 57, e6–e7. 10.1161/hypertensionaha.110.165142 PubMed DOI

Staessen J. A., Fagard R., Thijs L., Celis H., Arabidze G. G., Birkenhäger W. H., et al. . (1997). Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350, 757–764. PubMed

Tijssen J. G., Lubsen J. (1988). Early treatment of unstable angina with nifedipine and metoprolol- the HINT trial. J. Cardiovasc. Pharmacol. 12, S71–S77. 10.1097/00005344-198806121-00012 PubMed DOI

Tzourio C., Laurent S., Debette S. (2014). Is hypertension associated with an accelerated aging of the brain? Hypertension 63, 894–903. PubMed

WHO (2017). Dementia. Available online at: http://www.who.int/news-room/fact-sheets/detail/dementia [accessed June 2, 2018].

Yasar S., Corrada M., Brookmeyer R., Kawas C. (2005). Calcium channel blockers and risk of AD: the Baltimore longitudinal study of aging. Neurobiol. Aging 26, 157–163. 10.1016/j.neurobiolaging.2004.03.009 PubMed DOI

Activities of Daily Living and Associated Costs in the Most Widespread Neurodegenerative Diseases: A Systematic Review